PulmonologyPub Date : 2024-07-01DOI: 10.1016/j.pulmoe.2022.11.004
M. Lichtblau , S. Saxer , J. Müller , P. Appenzeller , C. Berlier , S.R. Schneider , L. Mayer , M. Furian , E.I. Schwarz , E.R. Swenson , K.E. Bloch , S. Ulrich
{"title":"Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: A randomized, double-blind, cross-over trial","authors":"M. Lichtblau , S. Saxer , J. Müller , P. Appenzeller , C. Berlier , S.R. Schneider , L. Mayer , M. Furian , E.I. Schwarz , E.R. Swenson , K.E. Bloch , S. Ulrich","doi":"10.1016/j.pulmoe.2022.11.004","DOIUrl":"10.1016/j.pulmoe.2022.11.004","url":null,"abstract":"<div><h3>Background</h3><p>The carbonic anhydrase inhibitor acetazolamide stimulates ventilation through metabolic acidosis mediated by renal bicarbonate excretion. In animal models, acetazolamide attenuates acute hypoxia-induced pulmonary hypertension (PH), but its efficacy in treating patients with PH due to pulmonary vascular disease (PVD) is unknown.</p></div><div><h3>Methods</h3><p>28 PVD patients (15 pulmonary arterial hypertension, 13 distal chronic thromboembolic PH), 13 women, mean±SD age 61.6±15.0 years stable on PVD medications, were randomised in a double-blind crossover protocol to 5 weeks acetazolamide (250mg b.i.d) or placebo separated by a ≥2 week washout period. Primary endpoint was the change in 6-minute walk distance (6MWD) at 5 weeks. Additional endpoints included safety, tolerability, WHO functional class, quality of life, arterial blood gases, and hemodynamics (by echocardiography).</p></div><div><h3>Results</h3><p>Acetazolamide had no effect on 6MWD compared to placebo (treatment effect: mean change [95%CI] -18 [-40 to 4]m, p=0.102) but increased arterial blood oxygenation through hyperventilation induced by metabolic acidosis. Other measures including pulmonary hemodynamics were unchanged. No severe adverse effects occurred, side effects that occurred significantly more frequently with acetazolamide vs. placebo were change in taste (22/0%), paraesthesia (37/4%) and mild dyspnea (26/4%).</p></div><div><h3>Conclusions</h3><p>In patients with PVD, acetazolamide did not change 6MWD compared to placebo despite improved blood oxygenation. Some patients reported a tolerable increase in dyspnoea during acetazolamide treatment, related to hyperventilation, induced by the mild drug-induced metabolic acidosis. Our findings do not support the use of acetazolamide to improve exercise in patients with PVD at this dosing.</p></div><div><h3>ClinicalTrials.gov Identifier</h3><p>NCT02755298</p></div>","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":"30 4","pages":"Pages 362-369"},"PeriodicalIF":10.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531043722002628/pdfft?md5=82004c4d139febe713929a0ef3b88629&pid=1-s2.0-S2531043722002628-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10526778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PulmonologyPub Date : 2024-07-01DOI: 10.1016/j.pulmoe.2024.01.004
Álvaro Fuentes-Martín , Luís Lourenço Graça
{"title":"Comparison of thoracic surgery training in the Iberian Peninsula: A call for European uniformity","authors":"Álvaro Fuentes-Martín , Luís Lourenço Graça","doi":"10.1016/j.pulmoe.2024.01.004","DOIUrl":"10.1016/j.pulmoe.2024.01.004","url":null,"abstract":"","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":"30 4","pages":"Pages 327-329"},"PeriodicalIF":10.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531043724000102/pdfft?md5=7b6d6182fdf0837921847f727333c866&pid=1-s2.0-S2531043724000102-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PulmonologyPub Date : 2024-06-01DOI: 10.1016/j.pulmoe.2024.04.006
E Clini, S Costi, M Girardis
{"title":"Rehabilitation and physiotherapists in the critical care medicine.","authors":"E Clini, S Costi, M Girardis","doi":"10.1016/j.pulmoe.2024.04.006","DOIUrl":"https://doi.org/10.1016/j.pulmoe.2024.04.006","url":null,"abstract":"","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PulmonologyPub Date : 2024-05-27DOI: 10.1016/j.pulmoe.2024.04.012
L Rinaldi, M Lugarà, V Simeon, F Perrotta, C Romano, C Iadevaia, C Sagnelli, L Monaco, C Altruda, M C Fascione, L Restivo, U Scognamiglio, N Laganà, R Nevola, G Oliva, M G Coppola, C Acierno, F Masini, E Pinotti, E Allegorico, S Tamburrini, G Vitiello, M Niosi, M L Burzo, G Franci, A Perrella, G Signoriello, V Frusci, S Mancarella, G Loche, G F Pellicano, M Berretta, G Calabria, L Pietropaolo, F G Numis, N Coppola, A Corcione, R Marfella, L E Adinolfi, A Bianco, F C Sasso, I de Sio
{"title":"Application and internal validation of lung ultrasound score in COVID-19 setting: The ECOVITA observational study.","authors":"L Rinaldi, M Lugarà, V Simeon, F Perrotta, C Romano, C Iadevaia, C Sagnelli, L Monaco, C Altruda, M C Fascione, L Restivo, U Scognamiglio, N Laganà, R Nevola, G Oliva, M G Coppola, C Acierno, F Masini, E Pinotti, E Allegorico, S Tamburrini, G Vitiello, M Niosi, M L Burzo, G Franci, A Perrella, G Signoriello, V Frusci, S Mancarella, G Loche, G F Pellicano, M Berretta, G Calabria, L Pietropaolo, F G Numis, N Coppola, A Corcione, R Marfella, L E Adinolfi, A Bianco, F C Sasso, I de Sio","doi":"10.1016/j.pulmoe.2024.04.012","DOIUrl":"https://doi.org/10.1016/j.pulmoe.2024.04.012","url":null,"abstract":"<p><strong>Background: </strong>The severe acute respiratory syndrome Coronarovirus-2 associated still causes a significant number of deaths and hospitalizations mainly by the development of respiratory failure. We aim to validate lung ultrasound score in order to predict mortality and the severity of the clinical course related to the need of respiratory support.</p><p><strong>Methods: </strong>In this prospective multicenter hospital-based cohort study, all adult patients with diagnosis of SARS-CoV-2 infection, performed by real-time reverse transcription polymerase chain reaction were included. Upon admission, all patients underwent blood gas analysis and lung ultrasound by expert operators. The acquisition of ultrasound scan was performed on 12 peculiar anatomic landmarks of the chest. Lung ultrasound findings were classified according to a scoring method, ranging 0 to 3: Score 0: normal A-lines. Score 1: multiple separated B-lines. Score 2: coalescent B-lines, alteration of pleural line. Score 3: consolidation area.</p><p><strong>Results: </strong>One thousand and seven patients were included in statistical analysis (male 62.4 %, mean age 66.3). Oxygen support was needed in 811 (80.5 %) patients. The median ultrasound score was 24 and the risk of having more invasive respiratory support increased in relation to higher values score computed. Lung ultrasound score showed negative strong correlation (rho: -0.71) with the P/F ratio and a significant association with in-hospital mortality (OR 1.11, 95 %CI 1.07-1.14; p < 0.001), even after adjustment with the following variables (age, sex, P/F ratio, SpO2, lactate, hypertension, chronic renal failure, diabetes, and obesity).</p><p><strong>Conclusions: </strong>The novelty of this research corroborates and validates the 12-field lung ultrasound score as tool for predicting mortality and severity clinical course in COVID-19 patients. Baseline lung ultrasound score was associated with in-hospital mortality and requirement of intensive respiratory support and predict the risk of IOT among COVID-19 patients.</p>","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141160498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PulmonologyPub Date : 2024-05-16DOI: 10.1016/j.pulmoe.2024.04.008
A Protti, R Tonelli, F Dalla Corte, D L Grieco, E Spinelli, S Spadaro, D Piovani, L S Menga, G Schifino, M L Vega Pittao, M Umbrello, G Cammarota, C A Volta, S Bonovas, M Cecconi, T Mauri, E Clini
{"title":"Development of clinical tools to estimate the breathing effort during high-flow oxygen therapy: A multicenter cohort study.","authors":"A Protti, R Tonelli, F Dalla Corte, D L Grieco, E Spinelli, S Spadaro, D Piovani, L S Menga, G Schifino, M L Vega Pittao, M Umbrello, G Cammarota, C A Volta, S Bonovas, M Cecconi, T Mauri, E Clini","doi":"10.1016/j.pulmoe.2024.04.008","DOIUrl":"https://doi.org/10.1016/j.pulmoe.2024.04.008","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Quantifying breathing effort in non-intubated patients is important but difficult. We aimed to develop two models to estimate it in patients treated with high-flow oxygen therapy.</p><p><strong>Patients and methods: </strong>We analyzed the data of 260 patients from previous studies who received high-flow oxygen therapy. Their breathing effort was measured as the maximal deflection of esophageal pressure (ΔPes). We developed a multivariable linear regression model to estimate ΔPes (in cmH<sub>2</sub>O) and a multivariable logistic regression model to predict the risk of ΔPes being >10 cmH<sub>2</sub>O. Candidate predictors included age, sex, diagnosis of the coronavirus disease 2019 (COVID-19), respiratory rate, heart rate, mean arterial pressure, the results of arterial blood gas analysis, including base excess concentration (BEa) and the ratio of arterial tension to the inspiratory fraction of oxygen (PaO<sub>2</sub>:FiO<sub>2</sub>), and the product term between COVID-19 and PaO<sub>2</sub>:FiO<sub>2</sub>.</p><p><strong>Results: </strong>We found that ΔPes can be estimated from the presence or absence of COVID-19, BEa, respiratory rate, PaO<sub>2</sub>:FiO<sub>2,</sub> and the product term between COVID-19 and PaO<sub>2</sub>:FiO<sub>2.</sub> The adjusted R<sup>2</sup> was 0.39. The risk of ΔPes being >10 cmH<sub>2</sub>O can be predicted from BEa, respiratory rate, and PaO<sub>2</sub>:FiO<sub>2</sub>. The area under the receiver operating characteristic curve was 0.79 (0.73-0.85). We called these two models BREF, where BREF stands for BReathing EFfort and the three common predictors: BEa (B), respiratory rate (RE), and PaO<sub>2</sub>:FiO<sub>2</sub> (F).</p><p><strong>Conclusions: </strong>We developed two models to estimate the breathing effort of patients on high-flow oxygen therapy. Our initial findings are promising and suggest that these models merit further evaluation.</p>","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PulmonologyPub Date : 2024-05-15DOI: 10.1016/j.pulmoe.2024.04.005
Hasan Bayram, Nur Konyalilar, Muge Akpinar Elci, Hadi Rajabi, G Tuşe Aksoy, Deniz Mortazavi, Özgecan Kayalar, Öner Dikensoy, Luis Taborda-Barata, Giovanni Viegi
{"title":"Issue 4-Impact of air pollution on COVID-19 mortality and morbidity: An epidemiological and mechanistic review.","authors":"Hasan Bayram, Nur Konyalilar, Muge Akpinar Elci, Hadi Rajabi, G Tuşe Aksoy, Deniz Mortazavi, Özgecan Kayalar, Öner Dikensoy, Luis Taborda-Barata, Giovanni Viegi","doi":"10.1016/j.pulmoe.2024.04.005","DOIUrl":"https://doi.org/10.1016/j.pulmoe.2024.04.005","url":null,"abstract":"<p><p>Air pollution is a major global environment and health concern. Recent studies have suggested an association between air pollution and COVID-19 mortality and morbidity. In this context, a close association between increased levels of air pollutants such as particulate matter ≤2.5 to 10 µM, ozone and nitrogen dioxide and SARS-CoV-2 infection, hospital admissions and mortality due to COVID 19 has been reported. Air pollutants can make individuals more susceptible to SARS-CoV-2 infection by inducing the expression of proteins such as angiotensin converting enzyme (ACE)2 and transmembrane protease, serine 2 (TMPRSS2) that are required for viral entry into the host cell, while causing impairment in the host defence system by damaging the epithelial barrier, muco-ciliary clearance, inhibiting the antiviral response and causing immune dysregulation. The aim of this review is to report the epidemiological evidence on impact of air pollutants on COVID 19 in an up-to-date manner, as well as to provide insights on in vivo and in vitro mechanisms.</p>","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PulmonologyPub Date : 2024-05-15DOI: 10.1016/j.pulmoe.2024.04.002
Q Xu, H Tian, L Feng, L Li, J Tang
{"title":"An extremely rare case of Langerhans cell hyperplasia in the thymus.","authors":"Q Xu, H Tian, L Feng, L Li, J Tang","doi":"10.1016/j.pulmoe.2024.04.002","DOIUrl":"https://doi.org/10.1016/j.pulmoe.2024.04.002","url":null,"abstract":"","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":" ","pages":""},"PeriodicalIF":11.7,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}